CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.
May 3rd 2024
From the death of author Paul Auster and musician Duane Eddy to King Charles’ visit to a cancer hospital, here’s what’s happening in the cancer space this week.
Opdivo Plus Chemo Did Not Improve Progression in EGFR-Mutated NSCLC
February 8th 2024Treatment with Opdivo (nivolumab) and chemotherapy did not significantly improve progression-free survival when compared with chemotherapy alone among some patients with EGFR-mutated metastatic non-small-cell lung cancer.
Tagrisso After Chemoradiation Reduced Progression Risk in NSCLC
February 7th 2024Treatment with Tagrisso after chemoradiation resulted in patients with EGFR-mutant stage 3 non-small cell lung cancer being nearly three times less likely to experience disease progression when compared with those treated with Imfinzi or subject to observation.
Remeron Increases Energy Consumption in NSCLC and Anorexia
February 3rd 2024For patients with advanced non-small cell lung cancer and anorexia, the use of the antidepressant Remeron has been shown to increase energy consumption, as researchers look for therapies to answer an issue faced by many patients.
Max Hypofractionated Concurrent Chemoradiation Dose Identified in NSCLC
January 25th 2024Researchers claim to have determined the maximum=tolerated dose and usage of hypofractionated concurrent chemoradiation with an adaptive stereotactic ablative radiotherapy boost for patients with locally advanced unresectable non-small cell lung cancer, according to recently published findings.
FDA to Review Applications for Potential Approval of Rybrevant for NSCLC Subset
January 2nd 2024The pharmaceutical company submitted applications for the FDA to consider approval of Rybrevant plus lazertinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or L858 substitution mutations.
Novel HER3-Directed Therapy Granted Priority Review for Previously Treated NSCLC
December 28th 2023The FDA granted priority review of patritumab deruxtecan for the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer previously treated with two or more systemic therapies.
Augtyro ‘Fills a Gap’ in the Treatment of ROS1-Positive NSCLC
December 4th 2023The recent FDA approval of the next-generation tyrosine kinase inhibitor Augtyro provides patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer another treatment option when the disease becomes resistant to other therapies.